First-Line Osimertinib May Up Survival in EGFR-Mutated NSCLC

THURSDAY, Dec. 5, 2019 -- For patients with previously untreated advanced non-small cell lung cancer (NSCLC) with an EGFR mutation, overall survival is longer for treatment with osimertinib rather than comparator tyrosine kinase inhibitors of the...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news